TRACON Pharmaceuticals, Inc.(TCON)

Description: TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

---

Keywords: Medicine Cancer Biopharmaceutical Drugs Breast Cancer Clinical Trial Clinical Development Lung Cancer Colorectal Cancer Macular Degeneration Treatment Of Breast Cancer Glioblastoma Blastoma Carcinoma Hepatocellular Carcinoma Targeted Therapy Sarcoma Age Related Macular Degeneration Renal Cell Carcinoma Soft Tissue Sarcoma Fibrotic Disease Therapeutics For Cancer Transgene Sa Treatment Of Lung Cancer Treatment Of Fibrotic Diseases

---

Home Page: www.traconpharma.com

TCON Technical Analysis

4350 La Jolla Village Drive
San Diego, CA 92122
United States
Phone: 858 550 0780

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)